Low molecular weight heparins in cardiovascular medicine

Minerva Cardioangiologica

Volumn 53, Issue 6, 2005, Pages 585-603

  De Lorenzo, F ^a,b   Dotsenko, O ^b   Kakkar, V V ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Acute coronary syndromes; Anticoagulants; Atherosclerosis; Cardiovascular diseases; Low molecular weight heparins; Myocardial infarction; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BEMIPARIN; CERTOPARIN; DALTEPARIN; DANAPAROID; DERMATAN SULFATE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; MESOGLYCAN; NADROPARIN; PARNAPARIN; PENTOSAN POLYSULFATE; PLACEBO; RAMIPRIL; REVIPARIN; TINZAPARIN; WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FOLLOW UP; HEMATOMA; HEPARINIZATION; HUMAN; LUNG EMBOLISM; META ANALYSIS; MORBIDITY; MORTALITY; ORAL BLEEDING; PHARMACODYNAMICS; PREVALENCE; REVIEW; RISK REDUCTION; SIDE EFFECT; SKIN BLEEDING; ST SEGMENT ELEVATION; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

ANTICOAGULANTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CORONARY DISEASE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 30644462859     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: Summary Article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation 2002;106:1893-900.
2. Swahn E, Wallentin L. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group. Am J Cardiol 1997;80(5A):25E-29E.
3. Wallentin L, Husted S, Kontny F, Swahn E. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study). Am J Cardiol 1997;80(5A):61E-63E.
4. Husted SE, Wallentin L, Lagerqvist B, Kontny F, Stahle E, Swahn E. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. Eur Heart J 2002;23:1213-8.
5. Klein W, Buchwald A, Hillis WS, Monrad S, Sanz G, Turpie AG et al. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease. Am J Cardiol 1997;80(5A):30E-34E.
6. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
7. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-601.
8. Antman EM, Cohen M, Radley D, McCabe C, Rush J, PremmereurJ et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-8.
9. Harrison J. Economic and practical implications on new therapies. Royal College of Physicians. Rhone-Poulenc Rorer symposium "The future of antithrombotics in cardiology". 1997
10. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 1999;20:1553-62.
11. Bijsterveld NR, Peters RJ, Murphy SA, Bernink PJ, Tijssen JG, Cohen M. Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) studies. J Am Coll Cardiol 2003;42:2083-9.
12. Michalis LK, Katsouras CS, Papamichael N, Adamides K, Naka KK, Goudevenos J et al. Enoxaparin versus inzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J 2003;146:304-10.
13. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A; Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238-44.
14. de Lemos JA, Blazing MA, Wiviott SD, Brady WE, White HD, Fox KA et al. A to Z Investigators. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. Eur Heart J 2004;25:1688-94.
15. Blazing MA, de Lemos JA, White HD, Fox KA, Verfleugt FW, Ardissino D et al. A to Z Investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004;292:55-64.
16. James S, Armstrong P, Califf R, Husted S, Kontny F, Niemminen M et al. Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. Eur Heart J 2002;23:1538-45.
17. Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Hamngton RA et al. NICE-3 Investigators. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 2003;146:628-34.
18. Cohen M, Theroux P, Borzak S, Frey MJ, White HD, Van Mieghem W et al. ACUTE II Investigators. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J 2002;144:470-7.
19. Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M et al. NICE 1 and NICE 4 Investigators. National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001;13:272-8.
20. Fox KA, Antman EM, Cohen M, Bigonzi F; ESSENCE/TIMI 11B Investigators. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol 2002;90:477-82.
21. Moser LR, Kalus JS. Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes. Ann Pharmacother 2004;38:2094-104. Epub 2004 Nov 9.
22. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S et al. SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
23. Frostfeldt G, Ahlberg G, Gustafsson G, Helmius G, Lindahl B, Nygren A. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction-a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999;33:627-33.
24. Simoons M, Krzeminska-Pakula M, Alonso A, Goodman S, Kali A, Loos U et al. AMI-SK Investigator. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 2002;23:1282-90.
25. Ross AM, Molhoek P, Lundergan C, Knudtson M, Draoui Y, Regalado L et al. HART II Investigators. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001;104:648-52.
26. Wallentin L, Dellborg DM, Lindahl B, Nilsson T, Pehrsson K, Swahn E. The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study. Clin Cardiol 2001;24(3 Suppl):I12-4.
27. Sinnaeve PR, Alexander JH, Bogaerts K, Belmans A, Wallentin L, Armstrong P et al. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. Am Heart J 2004;147:993-8.
28. Tatu-Chitoiu G, Teodorescu C, Capraru P, Guran M, Istratescu O, Dan M et al. Accelerated streptokinase and enoxaparin in ST-segment elevation acute myocardial infarction (the ASENOX study). Kardiol Pol 2004;60:441-6.
29. Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A et al. TETAMI Investigators. Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial. Circulation 2003;108(16 Suppl 1):III14-21.
30. Yusuf S, Mehta SR, Xie C, Ahmed RJ, Xavier D, Pais P et al. CREATE Trial Group Investigators. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005;293:427-35.
31. Kakkar VV, Iyengar SS, De Lorenzo F, Hargreaves JR, Kadziola ZA; FAMI Investigator Group. Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction. Indian Heart J 2000;52:533-9.
32. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52.
33. Baker DW, Wright RF. Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. JAMA 1994;272:1614-8.
34. Kyrle PA, Korninger C, Gossinger H, Glogar D, Lechner K, Niessner H et al. Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thromb Haemost 1985;54:521-3.
35. Fuster V, Gersh B, Guiliani E, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525-31.
36. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
37. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
38. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-8.
39. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-7.
40. Dries DL, Domanski MJ, Waclawiw MA, Gersh BJ. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol 1997;79:909-13.
41. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol 1987;60:1340-55.
42. Bassenge E, Fink B, Skatchkov M, Dikalov S. Endothelium and platelet activity in heart failure. J Card Fail 1996;2(4 Suppl):S203-8.
43. Sosin MD, Bhatia G, Davis RC, Lip G. Congestive heart failure and Virchow's triad: a neglected association. Wien Med Wochenschr 2003;153:411-6.
44. Fuster V, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326:242-50.
45. Jafri SM. Hypercoagulability in heart failure. Semin Thromb Haemost 1997;23:543-5.
46. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995;26:1376-98.
47. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):338S-400S.
48. Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148:157-64.
49. Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004;10:101-12.
50. De Lorenzo F, Newberry D, Scully M, Kadziola Z, Dawson G, Ranlall N et al. Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure. Am Heart J 2002;143:689.
51. De Lorenzo F, Xiao H, Scully M, Kadziola Z, Kakkar VV. Prethrombotic state and impaired fibrinolytic potential in coronary heart disease patients with left ventricular dysfunction. Blood Coagul Fibrinolysis 2003;14:67-75.
52. Monreal M, Kakkar AK, Caprini JA, Barba R, Uresandi F, Valle R et al. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry. J Thromb Haemost 2004;2:1892-8.
53. Priglinger U, Delle Karth G, Geppert A, Joukhadar C, Graf S, Berger R et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit Care Med 2003;31:1405-9.
54. Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol 2000;86(12B):48M-52M.
55. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-9. Epub 2004 Aug 2.
56. Offord R, Lloyd AC, Anderson P, Bearne A. Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. Pharm World Sci 2004:26:214-20.
57. Kelly J, Rudd A, Lewis R, Hunt BJ. Venous thromboembolism after acute stroke. Stroke 2001;32:262-7.
58. Kamphuisen PW, Agnelli G, Sebastianelli M. Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost 2005;3:1187-94.
59. Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-93.
60. Diener HC, Ringelstein EB, von Kummer R, Langohr HD, Bewermeyer H, Landgraf H et at. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators. Stroke 2001;32:22-9.
61. Vemmos KN, Tsivgoulis G, Spengos K, Manios E, Toumanidis S, Zakopoulos N et al. Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke. Am J Geriatr Pharmacother 2004;2:265-73.
62. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000;355:1205-10.
63. Bath PM, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001;358:702-10.
64. Hillbom M, Erila T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Enoxaparin is heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand 2002;106:84-92.
65. Woessner R, Grauer M, Bianchi O, Mueller M, Moersdorf S, Berlit P et al. Treatment with anticoagulants in cerebral events (TRACE). Thromb Haemost 2004;91:690-3.
66. Sandercock P, Counsell C, Stobbs SL. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database Syst Rev 2005;(2):CD000119.
67. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):483S-512S.
68. Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J. Low molecular weight heparin and prevention of postoperative deep vein thrombosis. Br Med J 1982;284:375-9.
69. Kakkar VV, Murray WJ. Efficacy and safety of low molecular weight heparin (CY216) in preventing postoperative venous thromboembolism: a cooperative study. Br J Surg 1985;72:786-91.
70. Kakkar VV, Murray WJ, Walters HL, Gelister J, Malone P, Jones D. Treatment of deep vein thrombosis using a low mol. wt. heparin (LMWH) (CY216) - a randomized trail. Thrombosis Haemostas 1985;64:35.
71. Kakkar W. Low-dose heparin to low molecular weight heparin porphylaxis: in pursuit of excellence - a personal perpective. J Thromb Haemost 2005;3:195-209.
72. Koppenhagen K, Adolf J, Matthes M, Troster E, Roder JD, Hass S et al. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thromb Haemost 1992;67:627-30.
73. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet 1993;341:259-65.
74. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152-6.
75. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992;305:913-20.
76. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
77. Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-5.
78. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541-6.
79. Hirsh J, Siragusa S, Cosmi B, Ginsberg JS. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost. 1995;74:360-3.
80. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-7.
81. Thomas DP. Does low molecular weight heparin cause less bleeding? Thromb Haemost 1997;78:1422-5.
82. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
83. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996;334:682-7.
84. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with ontravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized controlled trials. Ann Intern Med 2004;140:175-83.